Goldman Sachs Group Inc. Sells 34,304 Shares of Kura Oncology, Inc. $KURA

Key Points

• Goldman Sachs Group Inc. has reduced its stake in Kura Oncology by 4.0%, selling 34,304 shares and now owning 0.96% of the company, valued at approximately $5.47 million.
• Kura Oncology's CEO, Troy Edward Wilson, significantly increased his holdings by purchasing 50,000 shares at an average price of $8.20, raising his total ownership to 100,968 shares.
• Kura Oncology reported a loss of ($0.75) earnings per share, significantly missing analysts' expectations, with revenues of $15.29 million versus estimates of $64.95 million.

Goldman Sachs Group Inc. lowered its stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 4.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 828,781 shares of the company's stock after selling 34,304 shares during the period. Goldman Sachs Group Inc. owned 0.96% of Kura Oncology worth $5,470,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. State of Wyoming bought a new stake in Kura Oncology in the first quarter valued at $48,000. Pallas Capital Advisors LLC purchased a new position in Kura Oncology during the first quarter valued at $66,000. Flower City Capital purchased a new position in Kura Oncology during the first quarter valued at $79,000. Magnetar Financial LLC purchased a new position in Kura Oncology during the first quarter valued at $79,000. Finally, E Fund Management Co. Ltd. lifted its position in Kura Oncology by 18.9% during the first quarter. E Fund Management Co. Ltd. now owns 12,252 shares of the company's stock valued at $81,000 after buying an additional 1,951 shares during the period.

Insiders Place Their Bets

In other Kura Oncology news, CEO Troy Edward Wilson bought 50,000 shares of the firm's stock in a transaction on Monday, September 8th. The stock was acquired at an average price of $8.20 per share, with a total value of $410,000.00. Following the transaction, the chief executive officer owned 100,968 shares in the company, valued at $827,937.60. This represents a 98.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 6.40% of the company's stock.

Kura Oncology Price Performance

Shares of NASDAQ:KURA opened at $8.21 on Tuesday. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $21.40. The business has a 50-day simple moving average of $6.96 and a two-hundred day simple moving average of $6.57. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.16 and a current ratio of 6.16. The firm has a market cap of $712.60 million, a price-to-earnings ratio of -3.63 and a beta of 0.19.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.90). The business had revenue of $15.29 million during the quarter, compared to analyst estimates of $64.95 million. On average, analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Analysts Set New Price Targets

KURA has been the subject of several recent research reports. JMP Securities lowered their price objective on Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating for the company in a research report on Monday, August 11th. Guggenheim assumed coverage on Kura Oncology in a research report on Thursday, September 4th. They set a "neutral" rating for the company. Mizuho lowered their price target on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday, May 19th. Wall Street Zen raised Kura Oncology from a "sell" rating to a "hold" rating in a research report on Sunday, August 17th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Kura Oncology in a research report on Thursday, June 26th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, Kura Oncology has an average rating of "Moderate Buy" and a consensus target price of $24.10.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.